Prilosec/Nexium Alert Is Debut Of FDA’s Early Communication Of Safety Issues
Executive Summary
FDA's announcement of an ongoing safety investiation regarding a possible increased risk of cardiac events with AstraZeneca's Prilosec (omeprazole) and Nexium (esomeprazole) is the first test case of the agency's new policy of releasing emerging drug safety information
You may also be interested in...
Drug Safety Communications Are Not Crisis Management Tools, FDA Says
A new draft guidance explains the Center for Drug Evaluation and Research’s approach to communicating emerging drug safety information. Since 2010, Drug Safety Communications have replaced a variety of audience-focused tools laid out in a 2007 guidance, but FDA says public health alerts will be used to communicate about products that pose an immediate danger.
FDA Clears Drugs With Post-Market Safety Questions Faster Than It Re-labels
FDA's "1early communication" program for alerting the public about potential drug safety issues produces a clean bill of health for products about 40 percent of the time, according to an analysis by "The Pink Sheet." And those positive decisions come much quicker than labeling changes the program has produced for drugs where genuine concerns have emerged
FDA Clears Drugs With Post-Market Safety Questions Faster Than It Re-labels
FDA's "1early communication" program for alerting the public about potential drug safety issues produces a clean bill of health for products about 40 percent of the time, according to an analysis by "The Pink Sheet." And those positive decisions come much quicker than labeling changes the program has produced for drugs where genuine concerns have emerged